About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Daily Archives: February 13, 2007
Ketek Gets New Label
The FDA announced the issuance of a new label for Ketek (telithromycin) that strips away two indications for use of the drug – acute bacterial sinusitis and acute bacterial exacerbations of chronic bronchitis – and retaining the sole remaining indication, … Continue reading
Posted in Risk Management
Comments Off on Ketek Gets New Label